Oral cleft prevention program (OCPP)

BMC Pediatrics

Jeffrey C Murray⁸  Lorette Javois³  Hrishikesh Chakraborty²  Tyler Hartwell²  Steve Litavecz²  Rui Pereira⁶  Camilla Vila Nova Guimaraes⁴  Fernanda Queiros⁴  Carla Padovani⁴  Antonio Richieri-Costa⁷  Temis Felix¹  Danilo Moretti-Ferreira⁵  Norman Goco²  George L Wehby⁸ 

[1]Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

[2]RTI International, Durham, NC, USA

[3]Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA

[4]Hospital Santo Antônio- Centrinho: Obras Sociais Irmã Dulce, Salvador, Bahia, Brazil

[5]Genetic Counseling Service – Bioscience Institute, São Paulo State University, Botucatu, Sao Paulo, Brazil

[6]Instituto Materno Infantil Prof. Fernando Figueira, Recife, Pernambuco, Brazil

[7]Hospital de Reabilitação de Anomalias Craniofaciais, Bauru, Sao Paulo, Brazil

[8]University of Iowa, Iowa City, IA, USA

关键词: Prevention;    Vitamins;    Folic acid;    Birth defects;    Congenital anomalies;    Craniofacial anomalies;    Cleft palate;    Cleft lip;    Oral clefts;   

Others  :  1170602
DOI  :  10.1186/1471-2431-12-184

 received in 2012-10-05, accepted in 2012-11-13,  发布年份 2012

【 摘 要 】

Background

Oral clefts are one of the most common birth defects with significant medical, psychosocial, and economic ramifications. Oral clefts have a complex etiology with genetic and environmental risk factors. There are suggestive results for decreased risks of cleft occurrence and recurrence with folic acid supplements taken at preconception and during pregnancy with a stronger evidence for higher than lower doses in preventing recurrence. Yet previous studies have suffered from considerable design limitations particularly non-randomization into treatment. There is also well-documented effectiveness for folic acid in preventing neural tube defect occurrence at 0.4 mg and recurrence with 4 mg. Given the substantial burden of clefting on the individual and the family and the supportive data for the effectiveness of folic acid supplementation as well as its low cost, a randomized clinical trial of the effectiveness of high versus low dose folic acid for prevention of cleft recurrence is warranted.

Methods/design

This study will assess the effect of 4 mg and 0.4 mg doses of folic acid, taken on a daily basis during preconception and up to 3 months of pregnancy by women who are at risk of having a child with nonsyndromic cleft lip with/without palate (NSCL/P), on the recurrence of NSCL/P. The total sample will include about 6,000 women (that either have NSCL/P or that have at least one child with NSCL/P) randomly assigned to the 4 mg and the 0.4 mg folic acid study groups. The study will also compare the recurrence rates of NSCL/P in the total sample of subjects, as well as the two study groups (4mg, 0.4 mg) to that of a historical control group.

The study has been approved by IRBs (ethics committees) of all involved sites. Results will be disseminated through publications and presentations at scientific meetings.

Discussion

The costs related to oral clefts are high, including long term psychological and socio-economic effects. This study provides an opportunity for huge savings in not only money but the overall quality of life. This may help establish more specific clinical guidelines for oral cleft prevention so that the intervention can be better tailored for at-risk women.

ClinicalTrials.gov Identifier

NCT00397917

【 授权许可】

   
2012 Wehby et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Vanderas AP: Incidence of cleft lip, cleft palate, and cleft lip and palate among races: a review. Cleft Palate J 1987, 24(3):216-225.
• [2]Murray JC, Daack-Hirsch S, Buetow KH, Munger R, Espina L, Paglinawan N, Villanueva E, Rary J, Magee K, Magee W: Clinical and epidemiologic studies of cleft lip and palate in the Philippines. Cleft Palate Craniofac J 1997, 34(1):7-10.
• [3]Murray CJ, Gakidou EE, Frenk J: Health inequalities and social group differences: what should we measure? Bull World Health Organ 1999, 77(7):537-543.
• [4]Gakidou EE, Murray CJ, Frenk J: Defining and measuring health inequality: an approach based on the distribution of health expectancy. Bull World Health Organ 2000, 78(1):42-54.
• [5]Morrow RH, Hyder AA, Murray CJ, Lopez AD: Measuring the burden of disease. Lancet 1998, 352(9143):1859-1861.
• [6]Govindaraj R, Chellaraj G, Murray CJ: Health expenditures in Latin America and the Caribbean. Soc Sci Med 1997, 44(2):157-169.
• [7]Murray CJ, Lopez AD: The incremental effect of age-weighting on YLLs, YLDs, and DALYs: a response. Bull World Health Organ 1996, 74(4):445-446.
• [8]Conway H: Effect of supplemental vitamin therapy on the limitation of incidence of cleft lip and cleft palate in humans. Plast Reconstr Surg Transplant Bull 1958, 22(5):450-453.
• [9]Czeizal AE: Prevention of oral clefts through the use of folic acid and the multivitamin supplements: Evidence gaps. New york, Ny: Oxford University Press; 2002:443-457.
• [10]Munger RG, Sauberlich HE, Corcoran C, Nepomuceno B, Daack-Hirsch S, Solon FS: Maternal vitamin B-6 and folate status and risk of oral cleft birth defects in the Philippines. Birth Defects Res A Clin Mol Teratol 2004, 70(7):464-471.
• [11]Menegotto BG, Salzano FM: Epidemiology of oral clefts in a large South American sample. Cleft Palate Craniofac J 1991, 28(4):373-376. discussion 376–377
• [12]Mitchell LE, Christensen K: Analysis of the recurrence patterns for nonsyndromic cleft lip with or without cleft palate in the families of 3,073 Danish probands. Am J Med Genet 1996, 61(4):371-376.
• [13]Sperber G: Formation of the primary palate. In Cleft Lip and palate: from origin to treatment. Edited by Wyszynski D. New York, Ny: Oxford University Press; 2002:5-13.
• [14]Murray JC: Gene/environment causes of cleft lip and/or palate. Clin Genet 2002, 61(4):248-256.
• [15]Jones MC: Etiology of facial clefts: prospective evaluation of 428 patients. Cleft Palate J 1988, 25(1):16-20.
• [16]Fogh-Andersen P: The inheritance of hare Lip and cleft palate; contribution to the elucidation of the congenital clefts of the face. Copenhagen: Nyt Nordisk Forlag Arnold Busck; 1942.
• [17]Marazita M: Segregation analysis. In Cleft Lip and Palate: From Origin to Treatment. Edited by Wyszynski DF. New York: NyOxford University Press; 2002:222-233.
• [18]Mitchell L: Twin studies in oral cleft research. In Cleft Lip and palate: from origin to treatment. Edited by Wyszynski DF. New York, Ny: Oxford University Press; 2002:214-221.
• [19]Vieira AR, Romitti PA, Orioli IM, Castilla EE: Inheritance of cleft palate in South America: evidence for a major locus recessive. Orthod Craniofac Res 2003, 6(2):83-87.
• [20]Vieira AR, Romitti PA, Orioli IM, Castilla EE: Complex segregation analysis of 1,792 cleft lip and palate families in South America: 1967–1997. Pesqui Odontol Bras 2003, 17(2):161-165.
• [21]Vieira AR, Karras JC, Orioli IM, Castilla EE, Murray JC: Genetic origins in a South American clefting population. Clin Genet 2002, 62(6):458-463.
• [22]Ardinger HH, Buetow KH, Bell GI, Bardach J, VanDemark DR, Murray JC: Association of genetic variation of the transforming growth factor-alpha gene with cleft lip and palate. Am J Hum Genet 1989, 45(3):348-353.
• [23]Chenevix-Trench G, Jones K, Green AC, Duffy DL, Martin NG: Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor loci. Am J Hum Genet 1992, 51(6):1377-1385.
• [24]Mitchell LE, Healey SC, Chenevix-Trench G: Evidence for an association between nonsyndromic cleft lip with or without cleft palate and a gene located on the long arm of chromosome 4. Am J Hum Genet 1995, 57(5):1130-1136.
• [25]Stein J, Mulliken JB, Stal S, Gasser DL, Malcolm S, Winter R, Blanton SH, Amos C, Seemanova E, Hecht JT: Nonsyndromic cleft lip with or without cleft palate: evidence of linkage to BCL3 in 17 multigenerational families. Am J Hum Genet 1995, 57(2):257-272.
• [26]Wyszynski DF, Beaty TH, Maestri NE: Genetics of nonsyndromic oral clefts revisited. Cleft Palate Craniofac J 1996, 33(5):406-417.
• [27]Maestri NE, Beaty TH, Hetmanski J, Smith EA, McIntosh I, Wyszynski DF, Liang KY, Duffy DL, VanderKolk C: Application of transmission disequilibrium tests to nonsyndromic oral clefts: including candidate genes and environmental exposures in the models. Am J Med Genet 1997, 73(3):337-344.
• [28]Mitchell LE: Genetic epidemiology of birth defects: nonsyndromic cleft lip and neural tube defects. Epidemiol Rev 1997, 19(1):61-68.
• [29]Lidral AC, Romitti PA, Basart AM, Doetschman T, Leysens NJ, Daack-Hirsch S, Semina EV, Johnson LR, Machida J, Burds A, et al.: Association of MSX1 and TGFB3 with nonsyndromic clefting in humans. Am J Hum Genet 1998, 63(2):557-568.
• [30]Jezewski PA, Vieira AR, Nishimura C, Ludwig B, Johnson M, O'Brien SE, Daack-Hirsch S, Schultz RE, Weber A, Nepomucena B, et al.: Complete sequencing shows a role for MSX1 in non-syndromic cleft lip and palate. J Med Genet 2003, 40(6):399-407.
• [31]Zucchero TM, Cooper ME, Maher BS, Daack-Hirsch S, Nepomuceno B, Ribeiro L, Caprau D, Christensen K, Suzuki Y, Machida J, et al.: Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate. N Engl J Med 2004, 351(8):769-780.
• [32]Murray JC, Schutte BC: Cleft palate: players, pathways, and pursuits. J Clin Invest 2004, 113(12):1676-1678.
• [33]Vieira AR, Avila JR, Daack-Hirsch S, Dragan E, Felix TM, Rahimov F, Harrington J, Schultz RR, Watanabe Y, Johnson M, et al.: Medical sequencing of candidate genes for nonsyndromic cleft lip and palate. PLoS Genet 2005, 1(6):e64.
• [34]Jugessur A, Murray JC: Orofacial clefting: recent insights into a complex trait. Curr Opin Genet Dev 2005, 15(3):270-278.
• [35]Warkany J, Nelson R, Schraffenberger E: Congenital malformations induced in rats by maternal nutritional deficiency. Am J Dis Child 1943, 65:882-894.
• [36]Munger R: Maternal nutrition and oral clefts. New York, Ny: Oxford University Press; 2002:170-192.
• [37]Garcia AM, Fletcher T, Benavides FG, Orts E: Parental agricultural work and selected congenital malformations. Am J Epidemiol 1999, 149(1):64-74.
• [38]Khoury MJ, Calle EE, Joesoef RM: Recurrence of low birth weight in siblings. J Clin Epidemiol 1989, 42(12):1171-1178.
• [39]Werler MM, Lammer EJ, Rosenberg L, Mitchell AA: Maternal cigarette smoking during pregnancy in relation to oral clefts. Am J Epidemiol 1990, 132(5):926-932.
• [40]Lieff S, Olshan AF, Werler M, Strauss RP, Smith J, Mitchell A: Maternal cigarette smoking during pregnancy and risk of oral clefts in newborns. Am J Epidemiol 1999, 150(7):683-694.
• [41]Chung KC, Kowalski CP, Kim HM, Buchman SR: Maternal cigarette smoking during pregnancy and the risk of having a child with cleft lip/palate. Plast Reconstr Surg 2000, 105(2):485-491.
• [42]Wyszynski DF, Duffy DL, Beaty TH: Maternal cigarette smoking and oral clefts: a meta-analysis. Cleft Palate-Cran J 1997, 34(3):206-210.
• [43]Little J, Cardy A, Arslan MT, Gilmour M, Mossey PA: Smoking and orofacial clefts: a United Kingdom-based case–control study. Cleft Palate-Cran J 2004, 41(4):381-386.
• [44]Werler MM, Lammer EJ, Rosenberg L, Mitchell AA: Maternal alcohol Use in relation to selected birth defects. Am J Epidemiol 1991, 134(7):691-698.
• [45]Romitti PA, Lidral AC, Munger RG, Daack-Hirsch S, Burns TL, Murray JC: Candidate genes for nonsyndromic cleft lip and palate and maternal cigarette smoking and alcohol consumption: evaluation of genotype-environment interactions from a population-based case–control study of orofacial clefts. Teratology 1999, 59(1):39-50.
• [46]Shaw GM, Lammer EJ: Maternal periconceptional alcohol consumption and risk for orofacial clefts. J Pediatr 1999, 134(3):298-303.
• [47]Abrishamchian AR, Khoury MJ, Calle EE: The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: a population based case–control study. Genet Epidemiol 1994, 11(4):343-351.
• [48]Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR: Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case–control studies. BMJ 1998, 317(7162):839-843.
• [49]Carmichael SL, Shaw GM: Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999, 86(3):242-244.
• [50]Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P: First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 2003, 67(12):968-970.
• [51]Lasa CI, Ponciano PD: Update on the recurrence of cleft lip and palate. Surg Surg Spec 1989, 44:109-111.
• [52]Cembrano J, de Vera J, Joaquino J: Familial risk of recurrence of clefts of the lip and palate. Phil J Surg Spec 1995, 50:37-40.
• [53]Chung CS, Mi MP, Beechert AM: Genetic epidemiology of cleft lip with or without cleft palate in the population of Hawaii. Genet Epidemiol 1987, 4(6):415-423.
• [54]Croen LA, Shaw GM, Wasserman CR, Tolarova MM: Racial and ethnic variations in the prevalence of orofacial clefts in California, 1983–1992. Am J Med Genet 1998, 79(1):42-47.
• [55]Lopez-Camelo JS, Orioli IM: Heterogeneous rates for birth defects in Latin America: hints on causality. Genet Epidemiol 1996, 13(5):469-481.
• [56]Castilla EE, Lopez-Camelo JS, Campana H: Altitude as a risk factor for congenital anomalies. Am J Med Genet 1999, 86(1):9-14.
• [57]Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P: A haplotype map of the human genome. Nature 2005, 437(7063):1299-1320.
• [58]Etheredge AJ, Christensen K, Del Junco D, Murray JC, Mitchell LE: Evaluation of two methods for assessing gene-environment interactions using data from the Danish case–control study of facial clefts. Birth Defects Res A Clin Mol Teratol 2005, 73(8):541-546.
• [59]Hwang SJ, Beaty TH, Panny SR, Street NA, Joseph JM, Gordon S, McIntosh I, Francomano CA: Association study of transforming growth factor alpha (TGF alpha) TaqI polymorphism and oral clefts: indication of gene-environment interaction in a population-based sample of infants with birth defects. Am J Epidemiol 1995, 141(7):629-636.
• [60]Shaw GM, Wasserman CR, Lammer EJ, O'Malley CD, Murray JC, Basart AM, Tolarova MM: Orofacial clefts, parental cigarette smoking, and transforming growth factor-alpha gene variants. Am J Hum Genet 1996, 58(3):551-561.
• [61]Zeiger JS, Beaty TH, Liang KY: Oral clefts, maternal smoking, and TGFA: a meta-analysis of gene-environment interaction. Cleft Palate Craniofac J 2005, 42(1):58-63.
• [62]Beaty TH, Maestri NE, Hetmanski JB, Wyszynski DF, Vanderkolk CA, Simpson JC, McIntosh I, Smith EA, Zeiger JS, Raymond GV, et al.: Testing for interaction between maternal smoking and TGFA genotype among oral cleft cases born in Maryland 1992–1996. Cleft Palate Craniofac J 1997, 34(5):447-454.
• [63]Christensen K: The 20th century Danish facial cleft population–epidemiological and genetic-epidemiological studies. Cleft Palate Craniofac J 1999, 36(2):96-104.
• [64]Jugessur A, Lie RT, Wilcox AJ, Murray JC, Taylor JA, Saugstad OD, Vindenes HA, Abyholm FE: Cleft palate, transforming growth factor alpha gene variants, and maternal exposures: Assessing gene-environment interactions in case-parent triads. Genetic Epidemiology 2003, 25(4):367-374.
• [65]Mitchell LE, Murray JC, O'Brien S, Christensen K: Evaluation of two putative susceptibility loci for oral clefts in the Danish population. Am J Epidemiol 2001, 153(10):1007-1015.
• [66]van Rooij IA, Wegerif MJ, Roelofs HM, Peters WH, Kuijpers-Jagtman AM, Zielhuis GA, Merkus HM, Steegers-Theunissen RP: Smoking, genetic polymorphisms in biotransformation enzymes, and nonsyndromic oral clefting: a gene-environment interaction. Epidemiology 2001, 12(5):502-507.
• [67]Hartsfield JK Jr, Hickman TA, Everett ET, Shaw GM, Lammer EJ, Finnell RA: Analysis of the EPHX1 113 polymorphism and GSTM1 homozygous null polymorphism and oral clefting associated with maternal smoking. Am J Med Genet 2001, 102(1):21-24.
• [68]Lammer EJ, Shaw GM, Iovannisci DM, Van Waes J, Finnell RH: Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms. Epidemiology 2004, 15(2):150-156.
• [69]Lammer EJ, Shaw GM, Iovannisci DM, Finnell RH: Maternal smoking, genetic variation of glutathione s-transferases, and risk for orofacial clefts. Epidemiology 2005, 16(5):698-701.
• [70]Blanton SH, Patel S, Hecht JT, Mulliken JB: MTHFR is not a risk factor in the development of isolated nonsyndromic cleft lip and palate. Am J Med Genet 2002, 110(4):404-405.
• [71]Jugessur A, Wilcox AJ, Lie RT, Murray JC, Taylor JA, Ulvik A, Drevon CA, Vindenes HA, Abyholm FE: Exploring the effects of methylenetetrahydrofolate reductase gene variants C677T and A1298C on the risk of orofacial clefts in 261 Norwegian case-parent triads. Am J Epidemiol 2003, 157(12):1083-1091.
• [72]van Rooij IA, Vermeij-Keers C, Kluijtmans LA, Ocke MC, Zielhuis GA, Goorhuis-Brouwer SM, van der Biezen JJ, Kuijpers-Jagtman AM, Steegers-Theunissen RP: Does the interaction between maternal folate intake and the methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with or without cleft palate? Am J Epidemiol 2003, 157(7):583-591.
• [73]Gaspar DA, Matioli SR, de Cassia Pavanello R, Araujo BC, Alonso N, Wyszynski D, Passos-Bueno MR: Maternal MTHFR interacts with the offspring's BCL3 genotypes, but not with TGFA, in increasing risk to nonsyndromic cleft lip with or without cleft palate. Eur J Hum Genet 2004, 12(7):521-526.
• [74]Shelnutt KP, Kauwell GP, Chapman CM, Gregory JF 3rd, Maneval DR, Browdy AA, Theriaque DW, Bailey LB: Folate status response to controlled folate intake is affected by the methylenetetrahydrofolate reductase 677C–>T polymorphism in young women. J Nutr 2003, 133(12):4107-4111.
• [75]Shaw GM, Zhu H, Lammer EJ, Yang W, Finnell RH: Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects. Am J Epidemiol 2003, 158(8):747-752.
• [76]Vieira AR, Murray JC, Trembath D, Orioli IM, Castilla EE, Cooper ME, Marazita ML, Lennon-Graham F, Speer M: Studies of reduced folate carrier 1 (RFC1) A80G and 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms with neural tube and orofacial cleft defects. Am J Med Genet A 2005, 135(2):220-223.
• [77]Pei L, Zhu H, Zhu J, Ren A, Finnell RH, Li Z: Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial defects and congenital heart defects in China. Ann Epidemiol 2006, 16(5):352-356.
• [78]Botto LD, Olney RS, Erickson JD: Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C Semin Med Genet 2004, 125C(1):12-21.
• [79]Czeizel AE: The primary prevention of birth defects: Multivitamins or folic acid? Int J Med Sci 2004, 1(1):50-61.
• [80]Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM: Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 1995, 346(8972):393-396.
• [81]van Rooij IA, Ocke MC, Straatman H, Zielhuis GA, Merkus HM, Steegers-Theunissen RP: Periconceptional folate intake by supplement and food reduces the risk of nonsyndromic cleft lip with or without cleft palate. Prev Med 2004, 39(4):689-694.
• [82]Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA: Multivitamin supplementation and risk of birth defects. Am J Epidemiol 1999, 150(7):675-682.
• [83]Beaty TH, Wang H, Hetmanski JB, Fan YT, Zeiger JS, Liang KY, Chiu YF, Vanderkolk CA, Seifert KC, Wulfsberg EA, et al.: A case–control study of nonsyndromic oral clefts in Maryland. Ann Epidemiol 2001, 11(6):434-442.
• [84]Loffredo LC, Souza JM, Freitas JA, Mossey PA: Oral clefts and vitamin supplementation. Cleft Palate Craniofac J 2001, 38(1):76-83.
• [85]Itikala PR, Watkins ML, Mulinare J, Moore CA, Liu Y: Maternal multivitamin use and orofacial clefts in offspring. Teratology 2001, 63(2):79-86.
• [86]Hayes C, Werler MM, Willett WC, Mitchell AA: Case–control study of periconceptional folic acid supplementation and oral clefts. Am J Epidemiol 1996, 143(12):1229-1234.
• [87]Rouget F, Monfort C, Bahuau M, Nelva A, Herman C, Francannet C, Robert-Gnansia E, Cordier S: Periconceptional folates and the prevention of orofacial clefts: role of dietary intakes in France. Rev Epidemiol Sante Publique 2005, 53(4):351-360.
• [88]Krapels IP, van Rooij IA, Ocke MC, van Cleef BA, Kuijpers-Jagtman AM, Steegers-Theunissen RP: Maternal dietary B vitamin intake, other than folate, and the association with orofacial cleft in the offspring. Eur J Nutr 2004, 43(1):7-14.
• [89]Krapels IP, Rooij IA, Wevers RA, Zielhuis GA, Spauwen PH, Brussel W, Steegers-Theunissen RP: Myo-inositol, glucose and zinc status as risk factors for non-syndromic cleft lip with or without cleft palate in offspring: a case–control study. BJOG 2004, 111(7):661-668.
• [90]Tamura T, Munger RG, Corcoran C, Bacayao JY, Nepomuceno B, Solon F: Plasma zinc concentrations of mothers and the risk of nonsyndromic oral clefts in their children: a case–control study in the Philippines. Birth Defects Res A Clin Mol Teratol 2005, 73(9):612-616.
• [91]Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA: Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000, 343(22):1608-1614.
• [92]Peer LA, Bryan WH, Strean LP, Walker JC Jr, Bernhard WG, Peck GC: Induction of cleft palate in mice by cortisone and its reduction by vitamins. J Int Coll Surg 1958, 30(2):249-254.
• [93]Reynolds PR, Schaalje GB, Seegmiller RE: Combination therapy with folic acid and methionine in the prevention of retinoic acid-induced cleft palate in mice. Birth Defects Res A Clin Mol Teratol 2003, 67(3):168-173.
• [94]Bienengraber V, Malek FA, Moritz KU, Fanghanel J, Gundlach KK, Weingartner J: Is it possible to prevent cleft palate by prenatal administration of folic acid? An experimental study. Cleft Palate Craniofac J 2001, 38(4):393-398.
• [95]Malek FA, Moritz KU, Fanghanel J, Bienengraber V: Sex-related differences in procarbazine-induced cleft palate and microgenia and the anti-teratogenic effect of prenatal folic acid supplementation in rats. Ann Anat 2003, 185(5):465-470.
• [96]Malek FA, Moritz KU, Fanghanel J, Bienengraber V: Reduction of procarbazine-induced cleft palates by prenatal folic acid supplementation in rats. Pathol Res Pract 2004, 200(1):33-40.
• [97]Paros A, Beck SL: Folinic acid reduces cleft lip [CL(P)] in A/WySn mice. Teratology 1999, 60(6):344-347.
• [98]Fu SS, Sakanashi TM, Rogers JM, Hong KH, Keen CL: Influence of dietary folic acid on the developmental toxicity of methanol and the frequency of chromosomal breakage in the CD-1 mouse. Reprod Toxicol 1996, 10(6):455-463.
• [99]Burgoon JM, Selhub J, Nadeau M, Sadler TW: Investigation of the effects of folate deficiency on embryonic development through the establishment of a folate deficient mouse model. Teratology 2002, 65(5):219-227.
• [100]Elwood JM, Colquhoun TA: Observations on the prevention of cleft palate in dogs by folic acid and potential relevance to humans. N Z Vet J 1997, 45(6):254-256.
• [101]Hashmi SS, Waller DK, Langlois P, Canfield M, Hecht JT: Prevalence of nonsyndromic oral clefts in Texas: 1995–1999. Am J Med Genet A 2005, 134(4):368-372.
• [102]Canfield MA, Collins JS, Botto LD, Williams LJ, Mai CT, Kirby RS, Pearson K, Devine O, Mulinare J: Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study. Birth Defects Res A Clin Mol Teratol 2005, 73(10):679-689.
• [103]Simmons CJ, Mosley BS, Fulton-Bond CA, Hobbs CA: Birth defects in Arkansas: is folic acid fortification making a difference? Birth Defects Res A Clin Mol Teratol 2004, 70(9):559-564.
• [104]Ray JG, Meier C, Vermeulen MJ, Wyatt PR, Cole DE: Association between folic acid food fortification and congenital orofacial clefts. J Pediatr 2003, 143(6):805-807.
• [105]Castilla EE, Orioli IM, Lopez-Camelo JS, Dutra Mda G, Nazer-Herrera J: Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am J Med Genet A 2003, 123A(2):123-128.
• [106]Lopez-Camelo JS, Orioli IM, da Graca Dutra M, Nazer-Herrera J, Rivera N, Ojeda ME, Canessa A, Wettig E, Fontannaz AM, Mellado C, et al.: Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet A 2005, 135(2):120-125.
• [107]Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD: Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995–2002. Pediatrics 2005, 116(3):580-586.
• [108]Liu S, West R, Randell E, Longerich L, O'Connor KS, Scott H, Crowley M, Lam A, Prabhakaran V, McCourt C: A comprehensive evaluation of food fortification with folic acid for the primary prevention of neural tube defects. BMC Pregnancy Childbirth 2004, 4(1):20. BioMed Central Full Text
• [109]Mills JL, Signore C: Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res A Clin Mol Teratol 2004, 70(11):844-845.
• [110]Czeizel AE, Dudas I: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992, 327(26):1832-1835.
• [111]Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, et al.: Prevention of neural-tube defects with folic acid in china. China-U.S. Collaborative project for neural tube defect prevention. N Engl J Med 1999, 341(20):1485-1490.
• [112]Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL, Weedon J, Quadros EV: Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004, 350(2):134-142.
• [113]da Costa M, Sequeira JM, Rothenberg SP, Weedon J: Antibodies to folate receptors impair embryogenesis and fetal development in the rat. Birth Defects Res A Clin Mol Teratol 2003, 67(10):837-847.
• [114]Peer LA, Walker JC Jr, Meiger R: The dieffenbach bone-flap method of cleft palate repair. Plast Reconstr Surg 1964, 34:472-482.
• [115]Briggs RM: Vitamin supplementation as a possible factor in the incidence of cleft lip/palate deformities in humans. Clin Plast Surg 1976, 3(4):647-652.
• [116]Tolarova M: Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. Lancet 1982, 2(8291):217.
• [117]Tolarova M, Harris J: Reduced recurrence of orofacial clefts after periconceptional supplementation with high-dose folic acid and multivitamins. Teratology 1995, 51(2):71-78.
• [118]MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the medical research council vitamin study. Lancet 1991, 338:131-137.
• [119]Czeizel AE, Timar L, Sarkozi A: Dose-dependent effect of folic acid on the prevention of orofacial clefts. Pediatrics 1999, 104(6):e66.
• [120]Czeizel E: Prevention of developmental abnormalities with particular emphasis of primary prevention. Tsitol Genet 2002, 36(5):58-72.
• [121]Christensen K, Juel K, Herskind AM, Murray JC: Long term follow up study of survival associated with cleft lip and palate at birth. Brit Med J 2004, 328(7453):1405.
• [122]Waitzman NJ, Romano PS, Scheffler RM: Estimates of the economic costs of birth defects. Inquiry: a journal of medical care organization, provision and financing 1994, 31(2):188-205.
• [123]Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI: Stratified randomization for clinical trials. J Clin Epidemiol 1999, 52(1):19-26.
• [124]Mills JL, Von Kohorn I, Conley MR, Zeller JA, Cox C, Williamson RE, Dufour DR: Low vitamin B-12 concentrations in patients without anemia: the effect of folic acid fortification of grain. Am J Clin Nutr 2003, 77(6):1474-1477.
• [125]O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 1979, 35(3):549-556.
• [126]Lan KKG, Simon R, Halperin M: Stochastically curtailed tests in long-term clinical trials. Communications in Statistics-Sequential Analysis 1982, 1:207-219.